Current Advancements in the Treatment of Alzheimer’s Disease
DOI:
https://doi.org/10.47611/jsrhs.v11i4.3691Keywords:
alzheimer, dementia, neurodegeneration, amyloid, tau, electromagnetic treatment, stem cellAbstract
Alzheimer’s disease (AD) has been the most prevalent form of dementia since its initial discovery in the 20th century. Despite the technological innovation and groundbreaking research that has been developed and completed, there hasn’t been any reported fix that can cure its symptoms, presenting a need to find more effective therapeutic solutions. From targeting amyloid plaques to the tau regions of neurons in the brain, there have been several attractive targets that may hold the solution to curing AD. With many different experimental drugs and therapies being tested everyday, the purpose of this literature review is to summarize what some of the various treatments entail with regards to the neurobiology behind Alzheimer’s, how they affect those selected regions, as well as potential future therapeutic solutions for this disease.
Downloads
References or Bibliography
Dementia. (n.d.). Retrieved August 27, 2022, from https://www.who.int/news-room/fact-sheets/detail/dementia
Alzheimer’s Facts and Figures Report | Alzheimer’s Association. (n.d.). Retrieved August 27, 2022, from https://www.alz.org/alzheimers-dementia/facts-figures
Breijyeh, Z., & Karaman, R. (2020). Comprehensive Review on Alzheimer’s Disease: Causes and Treatment. Molecules, 25(24), 5789. https://doi.org/10.3390/molecules25245789
Cummings, J. L., Tong, G., & Ballard, C. (n.d.). Treatment Combinations for Alzheimer’s Disease: Current and Future Pharmacotherapy Options. Journal of Alzheimer’s Disease, 67(3), 779–794. https://doi.org/10.3233/JAD-180766
Alzheimer’s Disease Fact Sheet. (n.d.). National Institute on Aging. Retrieved August 27, 2022, from https://www.nia.nih.gov/health/alzheimers-disease-fact-sheet
PDB101: Molecule of the Month: Amyloid-beta Precursor Protein. (n.d.). RCSB: PDB-101. Retrieved August 27, 2022, from http://pdb101.rcsb.org/motm/79
Swanson, C. J., Zhang, Y., Dhadda, S., Wang, J., Kaplow, J., Lai, R. Y. K., Lannfelt, L., Bradley, H., Rabe, M., Koyama, A., Reyderman, L., Berry, D. A., Berry, S., Gordon, R., Kramer, L. D., & Cummings, J. L. (2021). A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimer’s Research & Therapy, 13, 80. https://doi.org/10.1186/s13195-021-00813-8
Rukmangadachar, L. A., & Bollu, P. C. (2021). Amyloid Beta Peptide. In StatPearls [Internet]. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK459119/
What are Amyloid Plaques? (2014, January 17). News-Medical.Net. https://www.news-medical.net/health/What-are-Amyloid-Plaques.aspx
Portelius, E., Dean, R. A., Andreasson, U., Mattsson, N., Westerlund, A., Olsson, M., Demattos, R. B., Racke, M. M., Zetterberg, H., May, P. C., & Blennow, K. (2014). β-site amyloid precursor protein-cleaving enzyme 1(BACE1) inhibitor treatment induces Aβ5-X peptides through alternative amyloid precursor protein cleavage. Alzheimer’s Research & Therapy, 6(5), 75. https://doi.org/10.1186/s13195-014-0075-0
Murphy, M. P., & LeVine, H. (2010). Alzheimer’s Disease and the β-Amyloid Peptide. Journal of Alzheimer’s Disease : JAD, 19(1), 311. https://doi.org/10.3233/JAD-2010-1221
Sadigh-Eteghad, S., Sabermarouf, B., Majdi, A., Talebi, M., Farhoudi, M., & Mahmoudi, J. (2015). Amyloid-Beta: A Crucial Factor in Alzheimer’s Disease. Medical Principles and Practice, 24(1), 1–10. https://doi.org/10.1159/000369101
Kandadi Muralidharan, K., Tong, X., Kowalski, K. G., Rajagovindan, R., Lin, L., Budd Haberlain, S., & Nestorov, I. (2022). Population pharmacokinetics and standard uptake value ratio of aducanumab, an amyloid plaque–removing agent, in patients with Alzheimer’s disease. CPT: Pharmacometrics & Systems Pharmacology, 11(1), 7–19. https://doi.org/10.1002/psp4.12728
Dunn, B., Stein, P., & Cavazzoni, P. (2021). Approval of Aducanumab for Alzheimer Disease—The FDA’s Perspective. JAMA Internal Medicine, 181(10), 1276–1278. https://doi.org/10.1001/jamainternmed.2021.4607
Avila, J., Jiménez, J. S., Sayas, C. L., Bolós, M., Zabala, J. C., Rivas, G., & Hernández, F. (2016). Tau Structures. Frontiers in Aging Neuroscience, 8, 262. https://doi.org/10.3389/fnagi.2016.00262
Gong, C.-X., & Iqbal, K. (2008). Hyperphosphorylation of Microtubule-Associated Protein Tau: A Promising Therapeutic Target for Alzheimer Disease. Current Medicinal Chemistry, 15(23), 2321–2328.
Shiells, H., Schelter, B. O., Bentham, P., Baddeley, T. C., Rubino, C. M., Ganesan, H., Hammel, J., Vuksanovic, V., Staff, R. T., Murray, A. D., Bracoud, L., Wischik, D. J., Riedel, G., Gauthier, S., Jia, J., Moebius, H. J., Hardlund, J., Kipps, C. M., Kook, K., … Wischik, C. M. (n.d.). Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal Dementia. Journal of Alzheimer’s Disease, 75(2), 501–519. https://doi.org/10.3233/JAD-191173
Wilcock, G. K., Gauthier, S., Frisoni, G. B., Jia, J., Hardlund, J. H., Moebius, H. J., Bentham, P., Kook, K. A., Schelter, B. O., Wischik, D. J., Davis, C. S., Staff, R. T., Vuksanovic, V., Ahearn, T., Bracoud, L., Shamsi, K., Marek, K., Seibyl, J., Riedel, G., … Wischik, C. M. (2018). Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer’s Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial. Journal of Alzheimer’s Disease: JAD, 61(1), 435–457. https://doi.org/10.3233/JAD-170560
Stem cells: What they are and what they do—Mayo Clinic. (n.d.). Retrieved August 27, 2022, from https://www.mayoclinic.org/tests-procedures/bone-marrow-transplant/in-depth/stem-cells/art-20048117
Wilcock, G. K., Gauthier, S., Frisoni, G. B., Jia, J., Hardlund, J. H., Moebius, H. J., Bentham, P., Kook, K. A., Schelter, B. O., Wischik, D. J., Davis, C. S., Staff, R. T., Vuksanovic, V., Ahearn, T., Bracoud, L., Shamsi, K., Marek, K., Seibyl, J., Riedel, G., … Wischik, C. M. (2018). Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer’s Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial. Journal of Alzheimer’s Disease: JAD, 61(1), 435–457. https://doi.org/10.3233/JAD-170560
Arendash, G., Cao, C., Abulaban, H., Baranowski, R., Wisniewski, G., Becerra, L., Andel, R., Lin, X., Zhang, X., Wittwer, D., Moulton, J., Arrington, J., & Smith, A. (2019). A Clinical Trial of Transcranial Electromagnetic Treatment in Alzheimer’s Disease: Cognitive Enhancement and Associated Changes in Cerebrospinal Fluid, Blood, and Brain Imaging. Journal of Alzheimer’s Disease: JAD, 71(1), 57–82. https://doi.org/10.3233/JAD-190367
Published
How to Cite
Issue
Section
Copyright (c) 2022 Varun Ajith; Ali Kalam
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.
